• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SGMT alert in real time by email
    SC 13G/A 1 p24-3285sc13ga.htm SAGIMET BIOSCIENCES INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _________________
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No.  1)*
     

    Sagimet Biosciences Inc.

    (Name of Issuer)
     

    Series A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    786700104

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 78670010413G/APage 1 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 78670010413G/APage 2 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 78670010413G/APage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,468,128 (including 74,200 Series A Common Stock issuable upon exercise of options)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 78670010413G/APage 4 of 7 Pages

     

     

    Item 1(a). Name of Issuer.
      Sagimet Biosciences Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer’s Principal Executive Offices.
      155 Bovet Road, Suite 303, San Mateo, CA 94402.

     

    Item 2(a). Name of Person Filing.
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of Series A common stock, par value $0.0001 per share (“Series A Common Stock”), of the Issuer held by (and underlying options held by) Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Series A Common Stock held by (and underlying options held by) Point72 Associates; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Series A Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Series A Common Stock, par value $0.0001 per share.

     

    Item 2(e). CUSIP Number.
      786700104

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.
       

     

     

    CUSIP No. 78670010413G/APage 5 of 7 Pages

     

     

    Item 4. Ownership.
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on September 30, 2024.
       
      Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Series A Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.  Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc.  The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Series A Common Stock reported herein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Series A Common Stock.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
       

     

     

    CUSIP No. 78670010413G/APage 6 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date:  November 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:

    /s/ Jason M. Colombo

      Name:  Jason M. Colombo
      Title:    Authorized Person
      POINT72 CAPITAL ADVISORS, INC.
       
      By:

    /s/ Jason M. Colombo

      Name:  Jason M. Colombo
      Title:    Authorized Person
       
      STEVEN A. COHEN
       
      By:

    /s/ Jason M. Colombo

      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

    Get the next $SGMT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGMT

    DatePrice TargetRatingAnalyst
    8/11/2025$28.00Outperform
    Wedbush
    8/7/2025$29.00Buy
    H.C. Wainwright
    7/24/2025$28.00Buy
    Canaccord Genuity
    12/6/2024$30.00Outperform
    Oppenheimer
    11/12/2024$12.00Buy
    UBS
    6/28/2024$23.00 → $6.00Buy → Neutral
    Goldman
    5/2/2024$32.00Buy
    H.C. Wainwright
    3/25/2024$26.00Outperform
    Leerink Partners
    More analyst ratings

    $SGMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Sagimet Biosciences with a new price target

    Wedbush initiated coverage of Sagimet Biosciences with a rating of Outperform and set a new price target of $28.00

    8/11/25 10:06:29 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Sagimet Biosciences with a new price target

    H.C. Wainwright resumed coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $29.00

    8/7/25 7:42:15 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Sagimet Biosciences with a new price target

    Canaccord Genuity initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $28.00

    7/24/25 7:28:22 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Happel David sold $598,115 worth of Series A Common Stock (65,478 units at $9.13), decreasing direct ownership by 9% to 689,722 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    7/23/25 4:16:25 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Martins Eduardo Bruno sold $75,607 worth of Series A Common Stock (8,277 units at $9.13), decreasing direct ownership by 7% to 106,936 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    7/23/25 4:15:22 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel and CCO Rozek Elizabeth sold $98,471 worth of Series A Common Stock (10,780 units at $9.13), decreasing direct ownership by 6% to 183,726 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    7/23/25 4:14:11 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

    Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 being developed for acne in the U.S. Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 SAN MATEO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial result

    8/13/25 7:30:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

    SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA. A webcast of the fireside chat will be available in the Investors & Media section of Sagimet's website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences  Sagimet is a clinical-stage biopharmaceutical company developing no

    8/5/25 7:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025

    SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 2:00 PM ET. To register, click here. The event will feature key opinion leader (KOL) Neal Bhatia, MD (Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego), who will join company management to review positive efficacy and tolerability results from a Phase 3 clinical trial evaluating denifanstat for the treatment of moderate to severe acne vulgar

    6/9/25 7:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Happel David bought $63,731 worth of Series A Common Stock (12,100 units at $5.27), increasing direct ownership by 2% to 639,200 units (SEC Form 4)

    4 - Sagimet Biosciences Inc. (0001400118) (Issuer)

    3/28/24 4:08:37 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    SEC Filings

    View All

    Sagimet Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

    8/14/25 5:02:06 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Sagimet Biosciences Inc.

    424B5 - Sagimet Biosciences Inc. (0001400118) (Filer)

    8/14/25 4:58:22 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sagimet Biosciences Inc. (0001400118) (Filer)

    8/13/25 7:36:20 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Leadership Updates

    Live Leadership Updates

    View All

    Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

    SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. "We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an

    5/6/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

    SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

    3/25/24 7:00:00 AM ET
    $IPSC
    $MIRM
    $RPHM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $SGMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Sagimet Biosciences Inc.

    SC 13G - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 5:05:18 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 4:31:38 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SGMT
    Financials

    Live finance-specific insights

    View All

    Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

    Denifanstat Phase 2b FASCINATE-2 clinical trial 52-week data was presented in June at the European Association for the Study of the Liver (EASL) Congress Preparations are ongoing to initiate a Phase 3 clinical development program for denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, joined the Board of Directors effective August 1, 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $188.5 million as of June 30, 2024 SAN MATEO, Calif., Aug. 14, 202

    8/14/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

    SAN MATEO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that it will host a conference call and webcast on Thursday, June 13, 2024, at 9.30 AM PT / 12:30 PM ET. The event will feature Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, who was the Principal Investigator on the Phase 2b FASCINATE-2 clinical trial and serves as a scientific advi

    6/10/24 8:00:00 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care